SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK821.62m
- SEK756.91m
Brief: Synact Pharma Improves Design Of Ongoing Phase 2A Study In iMN
Brief: Synact Pharma Recieves Pre-IND Response From The U.S. FDA
Brief: Synact Pharma Announces Outcome Of Rights Issue
Brief: Synact Pharma Reports Top-Line Results From Phase 2A Study Of AP1189 In Early Rheumatoid Arthritis Patients Experiencing Severe Disease Activity
Brief: Synact Pharma Q4 Pretax Loss Narrows To SEK 9.8 Million
Brief: SynAct Explores Conditions For Carrying Out Directed Share Issue
Brief: SynAct Pharma Prepares Move To Nasdaq Stockholm
Brief: Synact Pharma Gets Proceeds Of SEK 80 Million Through Issue
Brief: Synact Pharma Q3 Pretax Loss Widens To SEK 9.1 Million
Brief: Synact Pharma Announces Positive Interim Phase 2 Data Of AP1189 In Rheumatoid Arthritis
Brief: Synact Pharma Completes Part 1 Of Phase II Trial With AP1189 For Rheumatoid Arthritis
Brief: Synact Pharma Informs About Termination Of Coverage Agreement With Redeye
Brief: SynAct Pharma Q2 Pre-Tax Loss Narrows To SEK 5.9 Mln
Brief: SynAct Pharma Initiates RESOVIR Scientific And Clinical Collaboration To Explore Ap1189 In Viral Infections
Brief: SynAct Pharma Announces Outcome In The Exercise Of Warrants
Brief: Synact Pharma's Clinical Trial Approved By The Danish Medical Agency
Brief: SynAct Pharma Files Patent Application
Brief: SynAct: Initial Data From First Part Of Phase II Study Within RA
Brief: Synact Pharma Applies For Patent For Ap1189 Within Covid-19